Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
CGTX's Phase 2 SHIMMER study shows promising results in dementia treatment. CT1812 demonstrated significant improvements in behavioral, cognitive, and movement measures. 82% reduction in neuropsychiatric symptoms, particularly anxiety and hallucinations. Cash reserves of $22 million support operations into mid-2025. CGTX stock rose 93.45% following the positive study results.
View signal analysis